

Earlier Detection of Heart Attack, Stroke, and Leukemia Risks



CardioHemeRISK™

Patient Information Leaflet

LUCENCE

Many serious health conditions can strike without warning

Silent Threats. Smart Detection. CardioHemeRISK™

CardioHemeRISK™ is a simple blood test that detects subtle genetic changes linked to these silent threats. By analyzing your blood, the test provides a personalized risk score for heart attack, stroke, and leukemia — delivered in just 12 working days.

CardioHemeRISK™ Helps You Stay One Step Ahead

You and your doctor can take proactive steps to manage your health before symptoms appear. Consult your doctor today to assess your risk if you are a:



Healthy individual aged above 40 and below 80



Cancer survivor previously treated with chemotherapy



Healthy individual aged above 40 with additional risk factors for atherosclerotic disease such as family history, hypertension, hyperlipidemia



Individual with a history of atherosclerotic disease such as coronary artery disease (CAD) or ischemic stroke



1 in 4

Heart Attack

patients have no known risk factors.¹



1 in 5

Stroke

patients have no known risk factors.²



1 in 3

Leukemia

cases are diagnosed in the emergency room.³



1

Get your blood drawn



2

Test for genetic changes



3

Receive a CardioHemeRISK™ score in 12 working days

Results Interpretation

CardioHemeRISK™ Score	Predicted Risk		
	Heart Attack	Stroke	Leukemia
Neg (0.0)	●	●	●
Very Low (>0.0 to <0.5)	●	●	● ⁴
Low (0.5 to < 2.0)	●	●	● ⁵
Mid (2.0 to < 10.0)	●	●	●
High (≥ 10.0)	● ⁶	●	●

Risk categories are based on hazard ratios (HR) reported in studies of clonal hematopoiesis: ● Average Risk, Mildly Elevated Risk: HR ≤ 1.5
● Moderately Elevated Risk: HR > 1.5 to 2.0 ● High Risk: HR > 2.0

References: [4] [5] [6] The predicted risks for heart attack or leukemia are adjusted if the *JAK2* V617F variant is detected in your blood sample. [4] If the *JAK2* V617F variant is detected with a VAF < 0.5%, the predicted risk is adjusted to mildly elevated risk for leukemia. [5] If the *JAK2* V617F variant is detected with a VAF < 2.0%, the predicted risk is adjusted to moderately elevated risk for leukemia. [6] If the *JAK2* V617F variant is detected with a VAF ≥ 2.0%, the predicted risk is adjusted to significantly elevated risk for heart attack.

LUCENCE

This pamphlet is not intended for the purpose of providing medical advice. All information, content, and material of this pamphlet are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Always seek the advice of your physician or other qualified healthcare provider for information you may need regarding a medical condition.

www.lucence.com

Customer support:

Singapore

+65 6592 5102
sales.asean@lucence.com

Hong Kong

+852 5182 7199
sales.hk@lucence.com

Lucence Service Laboratory

211 Henderson Road #04-01/02,
Henderson Industrial Park,
Singapore 159552

Lucence Diagnostics Pte. Ltd.
is licenced by the Ministry of Health (Singapore) as a
Clinical Laboratory (License Number:L/17I0039/CLB/004/242)
under the Healthcare Services Act 2020.
GST Registered 201605840N.